Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2003. The report serves as a notification of changes in director interests regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within the GlaxoSmithKline US Retirement Savings Plan.
Material Changes
The primary material change reported is an increase in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of July 17, 2003, the fund's holdings increased from 18,791,937 to 18,854,830 shares at an average price of $37.77.
Management Commentary and Risks
The filing notes that the Retirement Savings Plan is a discretionary fund for current and former employees. Director Dr. J. P. Garnier is identified as potentially interested in the shares held within this fund, similar to other employee beneficiaries. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan (18,854,830).
- Confirm the average transaction price of $37.77 for the movement on July 17, 2003.
- Note that Dr. J. P. Garnier's interest is indirect through the discretionary employee fund.